CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has formed an exclusive collaboration with the University of California, San Francisco (UCSF) to evaluate the potential of an RNAi therapeutic targeting a heterotrimeric G protein alpha-subunit, known as G-alpha q or GNAQ, for the treatment of metastatic uveal melanoma. The collaboration is based on new data that UCSF scientists, along with collaborators, published in the journal Nature suggesting that GNAQ plays an important role in the development of uveal melanoma.
